Clinical Trial

Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy of Tislelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. The primary study hypotheses are that: Neoadjuvant and adjuvant Tislelizumab plus chemoradiotherapy, followed by adjuvant Tislelizumab and chemotherapy is superior to neoadjuvant chemoradiotherapy or chemotherapy, followed by adjuvant chemotherapy in terms of rate of Pathological Complete Response (pathCR) at the time of surgery.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-01-16.
Status change: Not Yet Recruiting → Recruiting 2023-04-17
Trial Details
NCT Number NCT05687357
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Gastric Cancer, Gastroesophageal-junction Cancer
Enrollment 140 participants
Start Date 2023-03-15
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2023-04-19